University of North Carolina-Chapel Hill Division of Hematology

Slides:



Advertisements
Similar presentations
Basic coagulation techniques and Quality control issues
Advertisements

Hematologic/Coagulation Cases in Critical Care
1. What is the sequence of the intrinsic pathway of coagulation?
Coagulation Bruno Sopko.
Pre-analytical factors that can affect coag test results
Initiation substances activate s by proteolysis a cascade of circulating precursor proteins which leads to the generation of thrombin which in turn converts.
OUTLINE: I.Historical Perspective. A. Development of Thromboelastography. B. The expansion and transition from Cardiac Surgery to Trauma. II.Traditional.
Basic Principles of Hemostasis
Blood Coagulation.
MLAB 1227: Coagulation Keri Brophy-Martinez
Bleeding time,clotting time, PT, and PTT
Approach to the Bleeding Patient
Hemostasis/Thrombosis I Normal Hemostasis/Thrombosis; Assessment of Clotting System.
Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.
Blood coagulation involves a biological amplification system in which relatively few initiation substances sequentially activate by proteolysis a cascade.
Week 6: Secondary Hemostasis Plasmatic factors Plasmatic factors Intrinsic pathway Intrinsic pathway Extrinsic pathway Extrinsic pathway Specimen Specimen.
MLAB 1227: C OAGULATION K ERI B ROPHY - M ARTINEZ Secondary Hemostasis Part Three.
Damaged Blood Vessels. On vessel injury
MISHA MAZHAR 2k10-NUST-BS-V&I-54.  Mutations in F8 or F9 genes.  Leads to lack of proteins made by these genes.  F8 responsible for making the blood.
Bleeding time,clotting time, PT, and PTT
Coagulation Cascade Ahmad Shihada Silmi Msc,FIBMS IUG Faculty of Science Medical Technology Dept.
Blood coagulation and fibrinolysis Professor Asim K. Duttaroy University of Oslo.
Hemostasis and Blood Coagulation
MLAB Coagulation Keri Brophy-Martinez
Roman Numerals. The Numbers I-1 II-2 III-3 IV-4 V-5 VI-6 VII-7 VIII-8 IX-9 X-10 C-100 D-500 M-1000.
Tests for the Evaluation of Lupus Anticoagulants Islamic University of Gaza.
General Approach of Haemostasis
Secondary Hemostasis Part One MLAB Coagulation Keri Brophy-Martinez.
HEMOSTASIS Secondary hemostasis.
©2007 Wortham Laboratories, Inc.
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
MIXING STUDIES General Approach of Haemostasis
Coagulation Concepts A review of hemostasis Answers are in the notes pages.
SCREENING COAGULATION STUDIES When & when NOT to do them.
In this exercise, two tests will be performed to screen for defective clotting factors. The formation of thrombin in the plasma samples will be inhibited.
Clot Formation Review with Animations
Dr. S. Parthasarathy MD DA DNB PhD (physio) Mahatma Gandhi medical college and research institute, puducherry – India Prothrombin time.
APTT. Causes of prolonged aPTTs: 1.Spurious (common to many Coag tests): – dilution (saline, Tx), underfilled specimen, clotted, prolonged tourniquet.
Investigation of Haemostasis MS. c. program Lab-9.
Activated Partial Thromboplastin Time (aPTT)
Laboratory Testing in Coagulation Coagulation Keri Brophy-Martinez.
PHYSIOLOGIC CONTROL OF HEMOSTASIS MLAB Coagulation Keri Brophy-Martinez.
Factor Assays Robert Gosselin MT (ASCP), CLS.
Hemodynamics 2.
Intrinsic pathway Extrinsic pathway Common pathway The extrinsic pathway was required the addition of an exogenous trigger (originally provided by tissue.
Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.
Approach to the Bleeding Child. Evaluation  History Current Bleeding Medical Family  Physical exam  Selected laboratory investigations.
Screening Hemostasis Assays CBC,PBS Thrombocytopenia, Thrombocytosis, Giant P PT Vit K deficiency,Liver d. DIC, VII,V, IX deficiency and Factor inhibitor.
거핵구 (Megakaryocytic). Thrombocyte(Platelets ) Platelet Satelitism ( 혈소판 위성현상 ) EDTA Pseudothrombocytopenia.
University of North Carolina-Chapel Hill Division of Hematology
Chapter 17 Coagulation Testing
Chapter 23. Bleeding disorders associated with coagulopathy
ПОРТФОЛИО профессиональной деятельности Белово 2015 Таюшовой Натальи Борисовны Преподавателя дисциплин «Химия», «Биология»
Platelets. Fig Hemostasis the process by which the bleeding is stopped from broken vessels. steps involved: Vascular spasm. Platelets plug formation.
MLAB Coagulation Keri Brophy-Martinez
Pre-analytical factors that can affect coag test results
These factors prevent blood clotting - in normal state.
General Approach of Haemostasis
General Principles of Hemostasis Kristine Krafts, M.D.
General Approach in Investigation of Hemostasis
University of North Carolina-Chapel Hill Division of Hematology
What is a Blood Clot? 9/18/2018 MEDC 604 Anti-coagulants.
Mixing Studies-aPTT or PT 1:1 Mix
and anti-thrombotic pharmocology Tom Williams
Coagulation and Anti-coagulation
Activated Partial Thromboplastin Time (aPTT)
How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults  Arif H. Kamal, MD, Ayalew.
Intrinsic pathway Formation of prothombin activator is the central event in the clotting pathway For its formation the pathway that is initiated by.
General Principles of Hemostasis Kristine Krafts, M.D.
Principles of Coagulation Screening II
Presentation transcript:

University of North Carolina-Chapel Hill Division of Hematology Coag Made Easy Alice Ma, M.D. University of North Carolina-Chapel Hill Division of Hematology August 26, 2004

Coagulation made easy The PTT Pathway The PT Pathway

X Coagulation made easy The PTT Pathway The PT Pathway The PT and the PTT pathway meet at factor X, because “X” marks the spot

X Coagulation made easy V The PTT Pathway The PT Pathway Factor V is a cofactor for factor X, and you can remember this because V fits into the notch of the X

X Coagulation made easy Prothrombin Thrombin The PTT Pathway The PT Pathway V X Prothrombin Thrombin Factor Xa converts prothrombin (Factor II) into thrombin, the most important enzyme on the planet

X Coagulation made easy Prothrombin Thrombin Fibrinogen Fibrin The PTT Pathway The PT Pathway V X Thrombin, among other things, converts the soluble molecule fibrinogen into a solid fibrin clot Prothrombin Thrombin Fibrinogen Fibrin

Coagulation made easy - the PT The PT Pathway PT has one less letter than PTT, and PT values are shorter than PTT values, because the pathway is shorter. It means that the PT pathway is also shorter and this is lucky, so the lucky PT pathway uses lucky factor 7 to activate factor X 7 V X Prothrombin Thrombin Fibrinogen Fibrin

Coagulation made easy - the aPTT The PTT Pathway XII The PTT pathway has all those hideous roman numerals. . . How are we going to remember them? Hmmmmm. . . . . . . XI IX V X VIII Prothrombin Thrombin Fibrinogen Fibrin

Coagulation made easy - the aPTT The PTT Pathway T Well, just remember that the PTT is a basic TENET of hematology. TENET stands for. . . . . . E N E V X T Prothrombin Thrombin Fibrinogen Fibrin

Coagulation made easy - the aPTT The PTT Pathway Twelve Eleven Nine Eight V X Ten Prothrombin Thrombin Fibrinogen Fibrin

Coag Made Easy: PT and PTT both Prolonged The PTT Pathway The PT Pathway V X These factors are in the common pathway Prothrombin (II) Fibrinogen

Coag Made Easy: Only PT Prolonged 7 Deficiency of Factor VII will prolong the PT but not the PTT

Coag Made Easy: Only PTT Prolonged Deficiencies of Factors 12, 11, 9 and 8 will prolong the PTT and not the PT. Remember that factor 10 is in the common pathway, and affects BOTH the PT and the PTT Twelve Eleven Nine Eight Ten

What matters clinically XII XI Deficiencies of factor XI, IX, VIII, VII. X, V, prothrombin and fibrinogen are clinically significant. Inhibitors of these factors are clinically significant. Deficiency of Factor XII, and the presence of the lupus anticoagulant are not. IX VIII VII X V Thrombin Fibrinogen Fibrin

Coagulation Made Easy- The Mixing Study Useful to differentiate etiologies of prolonged clotting in a coagulation assay. Patient’s plasma is mixed 50:50 with normal plasma. Coagulation assay is repeated. If “substantial” correction is noted after mix, suspect clotting factor deficiency. If no or minimal correction seen, suspect inhibitor.